GSK v Teva Is the Future of Skinny Labelling to be Reconsidered

Skinny labelling has long allowed generic drugs to be approved for non-patented indications, allowing them to enter the market before the brand-name drug’s patent for other indications expires. In the recent GSK v Teva lawsuits, skinny labelling did not protect Teva from patent infringement and $235 million in damages.